Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2011
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.The pharmacogenomics journal · 2018Pooled it
- A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.Breast cancer research : BCR · 2013Trial
- Endoxifen Concentration Is Associated with Recurrence-Free Survival in Hormone-Sensitive Breast Cancer Patients.Cancer research and treatment · 2025Article
- Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.European journal of breast health · 2023Article
- Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.European journal of clinical pharmacology · 2021Review
- Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial.NPJ breast cancer · 2021Article
- The effect ofOncoTargets and therapy · 2017Article
- CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.Breast cancer research and treatment · 2015Article
- Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.Seminars in oncology · 2015Review
- Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.Breast cancer research and treatment · 2013Article
- Pharmacogenomics of breast cancer therapy: an update.Pharmacology & therapeutics · 2013Review
- Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.Cancer discovery · 2013Article
- Pharmacogenomics of endocrine therapy in breast cancer.Journal of human genetics · 2013Review
- Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen.Pharmacogenomics and personalized medicine · 2013Article
- Cancer pharmacogenomics: strategies and challenges.Nature reviews. Genetics · 2013Review
- Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.Breast cancer research and treatment · 2012Article
- Tamoxifen and CYP2D6: a contradiction of data.The oncologist · 2012Review
- CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients.Pharmacogenomics and personalized medicine · 2012Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundControversy exists regarding the association between CYP2D6 enzyme activity and tamoxifen effectiveness in the adjuvant treatment of invasive breast cancer; however, this association in the primary prevention of breast cancer is unknown.
methodsWe conducted a nested case-control study in the context of the NSABP P1 and P2 prevention trials to determine the impact of CYP2D6 genotype, CYP2D6 inhibitor use, and metabolizer status (CYP2D6 genotype combined with CYP2D6 inhibitor use), on breast cancer events. Women who developed breast cancer (both noninvasive and invasive) while on 5 years of selective estrogen receptor modulators therapy (cases) were matched to controls free of breast cancer. Comprehensive CYP2D6 genotyping was conducted for alleles associated with absent (*3, *4, *5, and *6), reduced (*10, *17, and *41), and increased (*1XN and *2XN) enzyme activity. Information regarding the use of CYP2D6 inhibitors was recorded.
resultsA total of 591 cases were matched to 1,126 controls and DNA was genotyped in more than 97%. In patients treated with tamoxifen, there was no association of CYP2D6 genotype [OR (extensive/poor metabolizer): 0.90; 95% CI: 0.46-1.74, P = 0.74), use of a potent CYP2D6 inhibitor (OR 0.92; 95% CI: 0.575-1.486), or CYP2D6 metabolizer status (OR 1.03; 95% CI: 0.669-1.607) with breast cancer occurrence. Likewise, there was no association between any CYP2D6 metabolism parameter with breast cancer events in raloxifene-treated patients.
conclusionIn the NSABP P1 and P2 clinical trials, alterations in CYP2D6 metabolism are not associated with either tamoxifen or raloxifene efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.